Overexpression of macrophage migration inhibitory factor protects against pressure overload‐induced cardiac hypertrophy through regulating the miR‐29b‐3p/HBP1 axis

Liang Wen, Wei Chen, Cunjun Zhu, Jie Li, Juan Zhou, Minxia Zhang, Wenqiang Zhang, Qiang XuePhysiological 2024 · DOI

TL;DR

This study reveals that overexpressing macrophage migration inhibitory factor (MIF) protects against pressure overload-induced cardiac hypertrophy in mice. This protective effect is mediated by MIF's ability to upregulate miR-29b-3p, which in turn suppresses the expression of HBP1, a factor that exacerbates oxidative stress in cardiomyocytes.

What Problem Does This Paper Address?

Cardiac hypertrophy, an enlargement of heart muscle cells in response to increased workload, is a common precursor to heart failure. While it's an adaptive response, prolonged hypertrophy leads to detrimental functional changes. Researchers have identified various factors involved in this process, but the precise molecular mechanisms, particularly how certain protective molecules like Macrophage Migration Inhibitory Factor (MIF) exert their effects, remain incompletely understood. This paper aims to elucidate the specific pathway through which MIF protects against pressure overload-induced cardiac hypertrophy.

Methods

The researchers employed a multi-pronged approach:

  • In Vivo Model: They established a pressure overload-induced cardiac hypertrophy model in mice using Transverse Aortic Constriction (TAC). To investigate MIF's role, they used Adeno-associated virus serotype 9 (AAV9) vectors to overexpress MIF specifically in cardiac cells.
  • Cardiac Function Assessment: Transthoracic echocardiography was used to evaluate cardiac function, specifically ejection fraction, in the treated mice.
  • Histological and Cellular Analysis: Wheat germ agglutinin (WGA) staining was used to measure cardiomyocyte size, and Hematoxylin & Eosin (H&E) staining provided gross morphological insights.
  • Molecular Analysis: Quantitative PCR (qPCR) was used to measure the expression of key cardiac hypertrophy markers (ANP, BNP, β-MHC) and microRNAs (miRNAs). Western blotting was employed to assess protein levels of MIF and its downstream targets.
  • In Vitro Model: A mouse cardiomyocyte cell line (HL-1) was used to study the effects of Angiotensin-II (Ang-II) in inducing oxidative stress and hypertrophy. This model was also used to investigate the roles of MIF, miR-29b-3p, and HBP1.
  • miRNA and Target Validation: Bioinformatics tools were used to predict potential targets of miR-29b-3p. Dual-luciferase reporter assays and western blotting were used to confirm the direct interaction between miR-29b-3p and its predicted target, HMG box protein 1 (HBP1).
  • Oxidative Stress Assays: Levels of malondialdehyde (MDA), nicotinamide adenine dinucleotide (NADH), and superoxide dismutase (SOD) were measured using ELISA kits to assess oxidative stress. Reactive oxygen species (ROS) levels were quantified using DCFH-DA staining.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • MIF as a Cardiac Protector: The study strongly suggests that MIF is not just an inflammatory mediator but also possesses significant protective functions in the context of cardiac hypertrophy. This challenges a purely pro-inflammatory view of MIF in this specific context.
  • The miR-29b-3p/HBP1 Axis as a Key Mediator: The identification of miR-29b-3p as a crucial downstream effector of MIF's protective action, and HBP1 as its target, provides a novel mechanistic link. This axis appears to be central to how MIF mitigates hypertrophy-induced damage.
  • HBP1 as a Pro-Hypertrophic Factor: The finding that HBP1 overexpression exacerbates hypertrophy markers and oxidative stress, and that its suppression by miR-29b-3p is key to MIF's benefit, highlights HBP1 as a potential therapeutic target for counteracting hypertrophy.
  • MIF's Dual Role in Oxidative Stress: The paper demonstrates that MIF not only protects against hypertrophy but also directly combats Ang-II-induced oxidative stress in cardiomyocytes, further solidifying its cardioprotective role.

Key Results

  • In Vivo: Overexpression of MIF in TAC-treated mice significantly reduced heart weight, improved ejection fraction, and decreased cardiomyocyte size compared to control TAC mice. It also attenuated the expression of hypertrophic markers like ANP, BNP, and β-MHC.
  • In Vitro: In HL-1 cells, MIF overexpression reduced Ang-II-induced hypertrophy markers, proliferation, and oxidative stress (lower ROS, MDA, and NADH; higher SOD).
  • Mechanism: MIF overexpression led to a significant increase in miR-29b-3p levels. Inhibition of miR-29b-3p partially reversed the beneficial effects of MIF on hypertrophy markers and oxidative stress.
  • Target Validation: HBP1 was identified as a direct target of miR-29b-3p. Overexpression of HBP1 in HL-1 cells reversed the protective effects of MIF, increasing hypertrophy markers and oxidative stress.

Limitations and Future Work

  • MIF-miRNA Interaction Mechanism: The study acknowledges that the precise mechanism by which MIF positively regulates miR-29b-3p expression is not fully understood and warrants further investigation.
  • MIF's ROS Removal Mechanism: While MIF's role in reducing oxidative stress is demonstrated, the specific molecular mechanisms by which it regulates oxidative stress-related enzymes remain unclear.
  • Therapeutic Potential: The authors suggest that MIF could be a promising therapeutic target for cardiac hypertrophy, but further studies are needed to explore this potential.

The paper concludes that MIF, through the miR-29b-3p/HBP1 axis, offers a protective mechanism against pressure overload-induced cardiac hypertrophy, highlighting a potential new avenue for therapeutic intervention.

Summary updated

Abstract

Cardiac hypertrophy is an adaptive response to stressors such as high cardiac workload, which might lead to abnormal cardiac function and heart failure. Previous studies have indicated that macrophage migration inhibitory factor (MIF) might play a protective role in cardiac hypertrophy. Here, we aimed to illustrate the mechanism of MIF in protecting against pressure overload-induced cardiac hypertrophy. Transverse aortic constriction (TAC) mouse model was established and we found that overexpression of MIF protected against pressure overload-induced cardiac hypotrophy in TAC treated mice, as evidenced by significantly decreased the heart weight. In addition, transthoracic echocardiography showed that overexpression of MIF restored ejection fraction in TAC-treated mice. While TAC treatment resulted in a much larger cardiomyocyte size in mice, MIF overexpression notably decreased the cardiomyocyte size. Next, we demonstrated that MIF overexpression promoted the expression of miR-29b-3p which further downregulated the expression of its downstream target HMG box protein 1 (HBP1). Overexpression of HBP1 reversed the effect of MIF in alleviating Ang-II induced oxidative stress in cardiomyocytes. In conclusion, our findings suggest that MIF could attenuate pressure overload-induced cardiac hypertrophy through regulating the miR-29b-3p/HBP1 axis.
BibTeX
@inproceedings{wen2024overexpression,
  author = {Liang Wen and Wei Chen and Cunjun Zhu and Jie Li and Juan Zhou and Minxia Zhang and Wenqiang Zhang and Qiang Xue},
  title = {{Overexpression of macrophage migration inhibitory factor protects against pressure overload‐induced cardiac hypertrophy through regulating the miR‐29b‐3p/HBP1 axis}},
  booktitle = {Physiological},
  year = {2024},
  doi = {10.14814/phy2.16022},
}
Figure